Nasdaq · CIK 0001635088
ROIV Roivant Sciences Ltd.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $35.44 on Oct 9, 2026, +121% from the 52-week low and -15% from the high.
Last 90 days
Net insider value
-$16M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
6
$16M by 3 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
ROIVOct 9, 2026 · close 35.44
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Roivant Sciences Ltd., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Epperly Melissa B director sell | $641k 17,750 shares | -54% | +125% from low-15% from high | |
| 28Weak | Eric Venker President & Immunovant CEO sell | $7.3M 200,000 shares | -11% | +142% from low-13% from high | |
| 25Weak | Epperly Melissa B director sell | $196k 4,938 shares | -33% | - | |
| 20Weak | Meghan Fitzgerald director sell | $203k 5,112 shares | -12% | - | |
| 27Weak | Meghan Fitzgerald director sell | $798k 20,000 shares | -32% | +221% from low0% from high | |
| 28Weak | Eric Venker President & Immunovant CEO sell | $7.2M 200,000 shares | -11% | +191% from low-8% from high | |
| 48Moderate | Daniel Allen Gold director sell | $39M 1,694,614 shares | -9% | +153% from low0% from high | |
| 43Moderate | Matthew Gline CEO sell | $38M 1,740,000 shares | -10% | +141% from low-1% from high | |
| 40Moderate | Daniel Allen Gold director sell | $26M 1,300,000 shares | -7% | +124% from low-5% from high | |
| 35Weak | Eric Venker President & Immunovant CEO sell | $26M 1,711,000 shares | -64% | +66% from low-2% from high | |
| 27Weak | Matthew Gline CEO buy | $50k 3,315 shares | +0% | +66% from low-1% from high | |
| 45Moderate | Vivek Ramaswamy owner sell | $22M 1,775,749 shares | -5% | +39% from low-1% from high | |
| 23Weak | Eric Venker President & Immunovant CEO sell | $1.2M 100,000 shares | -6% | +29% from low-8% from high | |
| 15Weak | Eric Venker President & Immunovant CEO sell | $1.2M 100,000 shares | -6% | +26% from low-10% from high | |
| 18Weak | Eric Venker President & COO sell | $1.1M 100,000 shares | -6% | +26% from low-10% from high | |
| 45Moderate | Vivek Ramaswamy owner sell | $13M 1,142,273 shares | -3% | +26% from low-10% from high | |
| 45Moderate | Vivek Ramaswamy owner sell | $8.5M 748,230 shares | -2% | +23% from low-12% from high | |
| 58Moderate | Eric Venker President & COO sell | $11M 1,000,000 shares | -60% | +23% from low-12% from high | |
| 18Weak | Eric Venker President & COO sell | $1.1M 100,000 shares | -8% | +22% from low-13% from high | |
| 45Moderate | Vivek Ramaswamy owner sell | $10M 898,959 shares | -2% | +22% from low-13% from high | |
| 10Weak | Eric Venker President & COO sell | $1.0M 100,000 shares | -8% | +11% from low-21% from high | |
| 45Moderate | Rakhi Kumar Chief Accounting Officer sell | $2.4M 227,500 shares | -58% | - | |
| 48Moderate | Eric Venker President & COO sell | $4.1M 354,604 shares | -42% | - | |
| 23Weak | Eric Venker President & COO sell | $1.1M 100,000 shares | -14% | - | |
| 33Weak | Mayukh Sukhatme Pres&Chief Investment Officer sell | $11M 886,237 shares | -5% | - | |
| 33Weak | Mayukh Sukhatme Pres&Chief Investment Officer sell | $5.0M 412,584 shares | -2% | - | |
| 15Weak | Eric Venker President & COO sell | $1.1M 100,000 shares | -14% | - | |
| 35Weak | Eric Venker President & COO sell | $1.2M 100,000 shares | -14% | - |
Congressional trades
4 trades in ROIV disclosed by members of Congress under the STOCK Act. All congressional trades.
- Lisa C. McClainHouse · R-MI · last Nov 21, 20252 bought
2 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Lisa C. McClain House · R-MI | Sale | ROIV Roivant Sciences Ltd. - Common Shares | $1,001 to $15k | Oct 30, 2025 / Nov 21, 2025 22 days after the trade | Clerk |
Lisa C. McClain House · R-MI | Purchase | ROIV Roivant Sciences Ltd. - Common Shares | $1,001 to $15k | Oct 30, 2025 / Nov 21, 2025 22 days after the trade | Clerk |
Lisa C. McClain House · R-MI | Sale | ROIV Roivant Sciences Ltd. - Common Shares | $1,001 to $15k | Oct 31, 2025 / Nov 21, 2025 21 days after the trade | Clerk |
Lisa C. McClain House · R-MI | Purchase | ROIV Roivant Sciences Ltd. - Common Shares | $1,001 to $15k | Jun 17, 2025 / Aug 13, 2025 57 days after the trade | Clerk |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Epperly Melissa B director | MOption exercise Common Shares10b5-1 | +17,750 | $4.46 | $79k | 32,704 | 7 d ago |
| Oct 1, 2026 | Epperly Melissa B director | SOpen-market sale Common Shares10b5-1 | -16,850 | $36.08 | $608k | 15,854 | 7 d ago |
| Oct 1, 2026 | Epperly Melissa B director | SOpen-market sale Common Shares10b5-1 | -900 | $36.57 | $33k | 14,954 | 7 d ago |
| Oct 1, 2026 | Epperly Melissa B director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,750 | $0.00 | $0 | 151,416 | 7 d ago |
| Sep 30, 2026 | Eric Venker President & Immunovant CEO | MOption exercise Common Shares10b5-1 | +200,000 | $3.85 | $770k | 1,799,154 | 10 d ago |
| Sep 30, 2026 | Matthew Gline CEO | FTax withholding Common Shares | -76,171 | $36.57 | $2.8M | 16,583,774 | 10 d ago |
| Sep 30, 2026 | Mayukh Sukhatme President & CIO | FTax withholding Common Shares | -46,879 | $36.57 | $1.7M | 18,583,860 | 10 d ago |
| Sep 30, 2026 | Frank Torti President and Vant Chair | FTax withholding Common Shares | +40,309 | $36.57 | $1.5M | 13,495,893 | 10 d ago |
| Sep 30, 2026 | Eric Venker President & Immunovant CEO | SOpen-market sale Common Shares10b5-1 | -200,000 | $36.62 | $7.3M | 1,599,154 | 10 d ago |
| Sep 30, 2026 | Eric Venker President & Immunovant CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -200,000 | $0.00 | $0 | 3,644,834 | 10 d ago |
| Sep 20, 2026 | Jennifer Humes Chief Accounting Officer | FTax withholding Common Shares | -3,880 | $39.77 | $154k | 106,419 | 20 d ago |
| Sep 20, 2026 | Richard Pulik CFO | FTax withholding Common Shares | -2,129 | $39.77 | $85k | 269,681 | 20 d ago |
| Sep 16, 2026 | Ilan Oren director | AGrant or award Common Shares | +5,054 | $0.00 | $0 | 123,680 | 24 d ago |
| Sep 16, 2026 | Daniel Allen Gold director | AGrant or award Common Shares | +5,054 | $0.00 | $0 | 8,965,815 | 24 d ago |
| Sep 16, 2026 | Keith S Manchester director | AGrant or award Common Shares | +5,054 | $0.00 | $0 | 1,753,457 | 24 d ago |
| Sep 16, 2026 | James C Momtazee director | AGrant or award Common Shares | +5,054 | $0.00 | $0 | 111,959 | 24 d ago |
| Sep 16, 2026 | Epperly Melissa B director | AGrant or award Common Shares | +5,054 | $0.00 | $0 | 14,954 | 24 d ago |
| Sep 16, 2026 | Meghan Fitzgerald director | AGrant or award Common Shares | +5,054 | $0.00 | $0 | 41,162 | 24 d ago |
| Sep 16, 2026 | Daniel Allen Gold director | AGrant or award Stock Option (Right to Buy)derivative | +10,531 | $0.00 | $0 | 10,531 | 24 d ago |
| Sep 16, 2026 | James C Momtazee director | AGrant or award Stock Option (Right to Buy)derivative | +10,531 | $0.00 | $0 | 10,531 | 24 d ago |
| Sep 16, 2026 | Meghan Fitzgerald director | AGrant or award Stock Option (Right to Buy)derivative | +10,531 | $0.00 | $0 | 10,531 | 24 d ago |
| Sep 16, 2026 | Keith S Manchester director | AGrant or award Stock Option (Right to Buy)derivative | +10,531 | $0.00 | $0 | 10,531 | 24 d ago |
| Sep 16, 2026 | Ilan Oren director | AGrant or award Stock Option (Right to Buy)derivative | +10,531 | $0.00 | $0 | 10,531 | 24 d ago |
| Sep 16, 2026 | Epperly Melissa B director | AGrant or award Stock Option (Right to Buy)derivative | +10,531 | $0.00 | $0 | 10,531 | 24 d ago |
| Sep 15, 2026 | Epperly Melissa B director | SOpen-market sale Common Shares10b5-1 | -4,338 | $39.65 | $172k | 10,500 | 25 d ago |
| Sep 15, 2026 | Meghan Fitzgerald director | SOpen-market sale Common Shares10b5-1 | -4,712 | $39.68 | $187k | 36,508 | 25 d ago |
| Sep 15, 2026 | Epperly Melissa B director | SOpen-market sale Common Shares10b5-1 | -600 | $40.38 | $24k | 9,900 | 25 d ago |
| Sep 15, 2026 | Meghan Fitzgerald director | SOpen-market sale Common Shares10b5-1 | -400 | $40.45 | $16k | 36,108 | 25 d ago |
| Sep 10, 2026 | James C Momtazee director | FTax withholding Common Shares | -2,905 | $40.94 | $119k | 106,905 | 28 d ago |
| Sep 10, 2026 | Ilan Oren director | FTax withholding Common Shares | -2,378 | $40.94 | $97k | 118,626 | 28 d ago |
| Sep 10, 2026 | Epperly Melissa B director | FTax withholding Common Shares | -2,179 | $40.94 | $89k | 14,838 | 28 d ago |
| Sep 10, 2026 | Meghan Fitzgerald director | FTax withholding Common Shares | -1,743 | $40.94 | $71k | 41,220 | 28 d ago |
| Sep 10, 2026 | Daniel Allen Gold director | FTax withholding Common Shares | -5,133 | $40.94 | $210k | 8,960,761 | 28 d ago |
| Sep 8, 2026 | Meghan Fitzgerald director | MOption exercise Common Shares10b5-1 | +20,000 | $8.80 | $176k | 62,963 | 32 d ago |
| Sep 8, 2026 | Meghan Fitzgerald director | SOpen-market sale Common Shares10b5-1 | -20,000 | $39.90 | $798k | 42,963 | 32 d ago |
| Sep 8, 2026 | Meghan Fitzgerald director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 18,578 | 32 d ago |
| Aug 28, 2026 | Eric Venker President & Immunovant CEO | MOption exercise Common Shares10b5-1 | +200,000 | $3.85 | $770k | 1,799,154 | 41 d ago |
| Aug 28, 2026 | Eric Venker President & Immunovant CEO | SOpen-market sale Common Shares10b5-1 | -166,182 | $35.63 | $5.9M | 1,632,972 | 41 d ago |
| Aug 28, 2026 | Eric Venker President & Immunovant CEO | SOpen-market sale Common Shares10b5-1 | -33,818 | $36.44 | $1.2M | 1,599,154 | 41 d ago |
| Aug 28, 2026 | Eric Venker President & Immunovant CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -200,000 | $0.00 | $0 | 3,844,834 | 41 d ago |
| Dec 16, 2025 | Daniel Allen Gold director | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -275,000 | $22.93 | $6.3M | 17,772,727 | Dec 18, 2025 |
| Dec 16, 2025 | Daniel Allen Gold director | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -642,282 | $23.08 | $15M | 17,130,445 | Dec 18, 2025 |
| Dec 17, 2025 | Daniel Allen Gold director | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -432,718 | $23.05 | $10.0M | 16,697,727 | Dec 18, 2025 |
| Dec 17, 2025 | Daniel Allen Gold director | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -155,076 | $23.02 | $3.6M | 16,542,651 | Dec 18, 2025 |
| Dec 17, 2025 | Daniel Allen Gold director | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -189,538 | $23.17 | $4.4M | 16,353,113 | Dec 18, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | MOption exercise Common Shares | +234,096 | $4.06 | $950k | 17,521,177 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | SOpen-market sale Common Shares | -230,357 | $21.68 | $5.0M | 17,290,820 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | JOther Common Shares | -3,739 | $21.68 | $81k | 17,287,081 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | MOption exercise Common Shares | +1,363,711 | $12.68 | $17M | 18,650,792 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | SOpen-market sale Common Shares | -566,116 | $21.68 | $12M | 18,084,676 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | JOther Common Shares | -797,595 | $21.68 | $17M | 17,287,081 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | MOption exercise Common Shares | +2,272,852 | $12.68 | $29M | 19,559,933 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | SOpen-market sale Common Shares | -943,527 | $21.68 | $20M | 18,616,406 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | JOther Common Shares | -1,329,325 | $21.68 | $29M | 17,287,081 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | MOption exercise Stock Option (Right to Buy)derivative | -234,096 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | MOption exercise Stock Option (Right to Buy)derivative | -1,363,711 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 15, 2025 | Matthew Gline CEO | MOption exercise Stock Option (Right to Buy)derivative | -2,272,852 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Nov 19, 2025 | Daniel Allen Gold director | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -850,000 | $20.25 | $17M | 18,497,727 | Nov 21, 2025 |
| Nov 19, 2025 | Daniel Allen Gold director | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -150,000 | $20.20 | $3.0M | 18,347,727 | Nov 21, 2025 |
| Nov 19, 2025 | Daniel Allen Gold director | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -125,000 | $20.16 | $2.5M | 18,222,727 | Nov 21, 2025 |
| Nov 19, 2025 | Daniel Allen Gold director | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -175,000 | $20.24 | $3.5M | 18,047,727 | Nov 21, 2025 |
| Oct 20, 2025 | Epperly Melissa B director | AGrant or award Common Shares | +1,056 | $0.00 | $0 | 56,904 | Oct 22, 2025 |
| Sep 28, 2025 | Richard Pulik CFO | FTax withholding Common Shares | -2,341 | $15.17 | $36k | 389,508 | Sep 30, 2025 |
| Sep 20, 2025 | Richard Pulik CFO | FTax withholding Common Shares | -2,129 | $15.04 | $32k | 391,849 | Sep 23, 2025 |
| Sep 19, 2025 | Eric Venker President & Immunovant CEO | MOption exercise Common Shares10b5-1 | +1,000,000 | $3.85 | $3.9M | 2,653,585 | Sep 23, 2025 |
| Sep 19, 2025 | Eric Venker President & Immunovant CEO | SOpen-market sale Common Shares10b5-1 | -683,818 | $14.95 | $10M | 1,969,767 | Sep 23, 2025 |
| Sep 22, 2025 | Eric Venker President & Immunovant CEO | MOption exercise Common Shares10b5-1 | +462,374 | $3.85 | $1.8M | 2,432,141 | Sep 23, 2025 |
| Sep 22, 2025 | Eric Venker President & Immunovant CEO | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 2,532,141 | Sep 23, 2025 |
| Sep 22, 2025 | Eric Venker President & Immunovant CEO | SOpen-market sale Common Shares10b5-1 | -316,182 | $14.99 | $4.7M | 2,215,959 | Sep 23, 2025 |
| Sep 22, 2025 | Eric Venker President & Immunovant CEO | SOpen-market sale Common Shares10b5-1 | -100,000 | $15.01 | $1.5M | 2,115,959 | Sep 23, 2025 |
| Sep 23, 2025 | Eric Venker President & Immunovant CEO | SOpen-market sale Common Shares10b5-1 | -611,000 | $14.83 | $9.1M | 1,504,959 | Sep 23, 2025 |
| Sep 19, 2025 | Eric Venker President & Immunovant CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,000,000 | $0.00 | $0 | 7,038,897 | Sep 23, 2025 |
| Sep 22, 2025 | Eric Venker President & Immunovant CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -462,374 | $0.00 | $0 | 6,576,523 | Sep 23, 2025 |
| Sep 22, 2025 | Eric Venker President & Immunovant CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 6,476,523 | Sep 23, 2025 |
| Sep 18, 2025 | Matthew Gline CEO | POpen-market purchase Common Shares | +3,315 | $15.07 | $50k | 17,287,081 | Sep 18, 2025 |
| Sep 10, 2025 | Epperly Melissa B director | AGrant or award Common Shares | +14,524 | $0.00 | $0 | 57,509 | Sep 12, 2025 |
| Sep 10, 2025 | Meghan Fitzgerald director | AGrant or award Common Shares | +14,524 | $0.00 | $0 | 43,900 | Sep 12, 2025 |
| Sep 10, 2025 | Daniel Allen Gold director | AGrant or award Common Shares | +14,524 | $0.00 | $0 | 8,971,164 | Sep 12, 2025 |
| Sep 10, 2025 | Keith S Manchester director | AGrant or award Common Shares | +14,524 | $0.00 | $0 | 1,948,403 | Sep 12, 2025 |
| Sep 10, 2025 | James C Momtazee director | AGrant or award Common Shares | +14,524 | $0.00 | $0 | 111,194 | Sep 12, 2025 |
| Sep 10, 2025 | Ilan Oren director | AGrant or award Common Shares | +14,524 | $0.00 | $0 | 119,205 | Sep 12, 2025 |
| Sep 10, 2025 | Epperly Melissa B director | JOther Common Shares | -1,661 | $13.77 | $23k | 55,848 | Sep 12, 2025 |
| Sep 10, 2025 | Meghan Fitzgerald director | JOther Common Shares | -937 | $13.77 | $13k | 42,963 | Sep 12, 2025 |
| Sep 10, 2025 | Daniel Allen Gold director | JOther Common Shares | -5,270 | $13.77 | $73k | 8,965,894 | Sep 12, 2025 |
| Sep 10, 2025 | Keith S Manchester director | AGrant or award Stock Option (Right to Buy)derivative | +33,726 | $0.00 | $0 | 33,726 | Sep 12, 2025 |
| Sep 10, 2025 | James C Momtazee director | JOther Common Shares | -3,282 | $13.77 | $45k | 107,912 | Sep 12, 2025 |
| Sep 10, 2025 | Ilan Oren director | JOther Common Shares | -2,043 | $13.77 | $28k | 117,162 | Sep 12, 2025 |
| Sep 10, 2025 | Epperly Melissa B director | AGrant or award Stock Option (Right to Buy)derivative | +33,726 | $0.00 | $0 | 33,726 | Sep 12, 2025 |
| Sep 10, 2025 | Meghan Fitzgerald director | AGrant or award Stock Option (Right to Buy)derivative | +33,726 | $0.00 | $0 | 33,726 | Sep 12, 2025 |
| Sep 10, 2025 | Daniel Allen Gold director | AGrant or award Stock Option (Right to Buy)derivative | +33,726 | $0.00 | $0 | 33,726 | Sep 12, 2025 |
| Sep 10, 2025 | James C Momtazee director | AGrant or award Stock Option (Right to Buy)derivative | +33,726 | $0.00 | $0 | 33,726 | Sep 12, 2025 |
| Sep 10, 2025 | Ilan Oren director | AGrant or award Stock Option (Right to Buy)derivative | +33,726 | $0.00 | $0 | 33,726 | Sep 12, 2025 |
| Sep 3, 2025 | Vivek Ramaswamy owner | SOpen-market sale Common Shares | -1,195,000 | $12.50 | $15M | 36,089,108 | Sep 5, 2025 |
| Sep 4, 2025 | Vivek Ramaswamy owner | SOpen-market sale Common Shares | -194,933 | $12.92 | $2.5M | 35,894,175 | Sep 5, 2025 |
| Sep 5, 2025 | Vivek Ramaswamy owner | SOpen-market sale Common Shares | -385,816 | $12.96 | $5.0M | 35,508,359 | Sep 5, 2025 |
| Aug 28, 2025 | Richard Pulik CFO | FTax withholding Common Shares | -2,340 | $11.94 | $28k | 393,978 | Sep 2, 2025 |
| Aug 20, 2025 | Richard Pulik CFO | FTax withholding Common Shares | -1,235 | $11.72 | $14k | 396,318 | Aug 22, 2025 |
| Aug 20, 2025 | Eric Venker President & Immunovant CEO | FTax withholding Common Shares10b5-1 | -7,051 | $11.72 | $83k | 1,653,585 | Aug 22, 2025 |
| Aug 20, 2025 | Eric Venker President & Immunovant CEO | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 1,753,585 | Aug 22, 2025 |
| Aug 20, 2025 | Eric Venker President & Immunovant CEO | SOpen-market sale Common Shares10b5-1 | -100,000 | $11.72 | $1.2M | 1,653,585 | Aug 22, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Epperly Melissa Bdirector
- Meghan Fitzgeralddirector
- Matthew GlineCEO
- Daniel Allen Golddirector
- Jennifer HumesChief Accounting Officer
- Rakhi KumarChief Accounting Officer
- Keith S Manchesterdirector
- James C Momtazeedirector
- Ilan Orendirector
- Richard PulikCFO
- Vivek Ramaswamyowner
- Mayukh SukhatmePresident & CIO
- Frank TortiPresident and Vant Chair
- Eric VenkerPresident & Immunovant CEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.